Menopause at Work:
Why Integration Beats Innovation
Introducing the 3H Framework™. A new employer roadmap backed by 25+ peer-reviewed sources across clinical, organizational, and health economics research.
THE PROBLEM
Menopause is invisible in the systems designed to support it.
It is invisible in claims data, invisible in benefits communications, and invisible in formulary design. This invisibility costs U.S. employers $26.6 billion annually, not because solutions don't exist, but because the problem itself goes unrecognized.
of women aged 45 to 64 have menopause recorded as a diagnosis, despite 100% being in perimenopause at minimum. Symptoms like anxiety, insomnia, and joint pain are coded as standalone conditions, never connected to their hormonal root cause. Employers can't address what they can't see.
Three Systemic Pain Points
Pain Point #1
The Benefits Gap
Menopause symptoms like anxiety, insomnia, and joint pain are coded as general conditions. Employers can't see menopause in their own claims data. Even when benefits exist, 86% of employees are confused about what's available, and fewer than one-third of women are aware of their menopause-related benefits.
Pain Point #2
The Awareness and Training Trap
Awareness is important, but it isn't enough. Awareness campaigns generate attention but not action. Certification programs create credentials but not capability. Manager training alone produces no sustained behavioral change without structural support.
Pain Point #3
The Formulary Wall and Treatment Gaps
Even when menopause is diagnosed, treatment access is often blocked by formulary restrictions, prior authorization, and cost barriers, despite many of the medications being generic. Women who need FDA-approved therapies often cannot get them through employer plans.
Get the 3H Framework™ Report
23 pages of evidence-based research. 25+ peer-reviewed sources. The business case and roadmap for workplace menopause support that actually works.
We respect your privacy. No spam, ever.
EARNINGS DECLINE
Symptomatic women experience a 10% earnings reduction within four years of menopause diagnosis. But the penalty is not biological or inevitable. Women with education, access, and treatment support suffered far less. Those prescribed and willing to take HRT experienced smaller declines.
"A penalty tied to biology would be eradicated with better structural support in healthcare and organizations, which benefits all employees, not just midlife women."
— Menopause at Work: Why Integration Beats Innovation (Fleming, 2026)
The 3H Framework™
Evidence-based approach that addresses both the "should we?" and "how do we do it right?" questions.
Most organizations do nothing. The few that act rely on manager menopause training, which research shows produces no sustained behavioral change (Hardy et al., 2018). The 3H Framework™ builds universal leadership capability that drives measurable retention. The 3H Healthcare Access Audit is how the framework is put to work inside your organization.
HEALTHCARE
We audit your medical and pharmacy benefits, assess how they're communicated, and optimize what you already have before investing in new solutions.
What You Get:
- Benefits analysis and formulary review
- Communications audit and strategy
- Educational resources for employees
HELP
We train leaders in our 3Cs Method™ of Compassionate Leadership, equipping them to handle all difficult conversations, not just menopause. This universal approach prevents inadvertent stigmatization.
What You Get:
- Compassionate leadership training (the 3Cs Method™)
- Menopause 101 and allyship workshops
- Self-advocacy training for employees
HRT & ACCESS
22 years of pharmaceutical access experience. We help organizations navigate the complex landscape of menopause therapies and optimize coverage.
What You Get:
- Formulary optimization recommendations
- Benefits team education on treatments
- Clinical education resources
Ready to get started? Schedule a consultation →
The Cost of Inaction
A model built to survive a CFO's scrutiny.
Typical annual cost for a 1,000-person employer, stated at the conservative floor
Published and federal sources, each named where it is used
Aligned to the budget-impact standards pharmaceutical companies use
Ask us the hard questions
Isn't some of this research funded by drug companies?
Two of twenty sources are, and we say so on the sheet itself. They are used because no independent equivalent exists, and the model lets you test the number with those inputs discounted.
Self-reported productivity loss isn't proof of cause.
Correct, and that is true of every workplace productivity study ever published. We use the lowest published rates, show the assumption, and let you cut it further.
Why trust a number from a firm that sells consulting?
Because the model is designed so you do not have to trust us. Every input is visible, every source is named, every assumption is adjustable, and the default is the most cautious one.
Have a harder question? Bring it to a discovery call. We will answer it with your numbers on the table.
Book a Discovery Call →Under The Hood
Built to Be Tested
Scrutiny is welcome. Every claim we make has a paper trail.
Defined Criteria
Every audit scores the same criteria across three domains. The same yardstick for every organization, every time.
Stress Tests
The cost model was run through hundreds of scenarios before a single client saw it. The edge cases are already found.
Approved Protocol
Our national research runs under independent ethics review, the same standard clinical studies meet.
Cited Scores
Every audit score traces to one of your own documents. You can check our work line by line.
Or book a discovery call and see it applied to your organization.
National Research Partnership with the Society for Women's Health Research
The Fuchsia Tent and SWHR partnered on a comprehensive, Pearl IRB approved U.S. study of workplace menopause support: a national survey of 1,110 participants with all 12 protocol subgroups powered, plus regional roundtables in Boston, Houston, Chicago, and Los Angeles. The study captures voices typically missing from the menopause conversation, including male decision-makers, frontline workers, and women of color. The co-branded findings release in fall 2026, and this framework is what those findings will test.
About the Author
Kacy Fleming, MA
Organizational Psychologist | Workplace Strategist
Kacy Fleming is the Founder and CEO of The Fuchsia Tent, a workplace menopause strategy firm, and Kacy Fleming Consulting, a leadership development consultancy built around the proprietary 3Cs Method™ of Compassionate Leadership. She holds an M.A. in Organizational Psychology from William James College.
A former Head of Global Well-Being at Takeda Pharmaceuticals, where she designed and managed programs for 50,000 employees across 80 countries, Kacy brings 22 years of pharmaceutical industry expertise spanning market access, health economics, and employer strategy. She is a TEDx speaker, LinkedIn Top Voice, and three-time Business Group on Health Award recipient, and her research has been featured in Forbes, Fast Company, Business Insider, and Authority Magazine.
Kacy@thefuchsiatent.com | thefuchsiatent.com | kacyfleming.com